We propose to continue Case-Control Surveillance (CCS) to assess the effects of prescription and nonprescription medications and other factors on the risk of cancers. Multiple case-control studies are conducted within a single data collection system. Nurse-interviewers in participating hospitals administer standard questionnaires to patients admitted for recently diagnosed cancers and other illnesses to obtain information on prescription and nonprescription medication use and on potential confounders or modifiers of exposure-disease associations. Data collection includes information on the newly popular class of nonprescription medications, herbals, and we have modified our drug dictionary in order to code these preparations. DNA is collected (from buccal cell samples) to allow for assessment of modification of drug disease associations by inherited genotype. We will continue to interview new cases and controls and to collect buccal samples. Enrollment of new patients is necessary because new drugs are constantly being introduced to the market, prescription drugs continue to be switched to nonprescription, and nonprescription drugs including herbals which have only recently become widely used are not otherwise monitored. Some herbals have been shown to have carcinogenic effects, affect estrogen levels, and influence the cytochrome p450 system involved with drug metabolism. One focus of CCS analyses will be the relation of the widely used drug classes, statins, histamine H2 antagonists, and selective serotonin uptake inhibitors, to risk of common cancers. We will also assess the relation of use of herbals to these cancers because the effects of these substances on cancer risk are largely unknown. We will assess modification by specific genetic polymorphisms of the relation of colon and breast cancer risk to use of nonsteroidal anti-inflammatory drugs. The usefulness of CCS for quantifying positive and inverse associations with cancer risk, documenting safety, and discovering associations has been extensively documented. Other systems do not have the capacity to assess a range of drug/genotype interactions or to systematically assess nonprescription drugs. CCS results have repeatedly been confirmed in other studies, indicating the success of efforts to minimize bias. CCS is a unique resource for cancer epidemiology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-SNEM-5 (02))
Program Officer
Kasten-Sportes, Carol H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston University
Public Health & Prev Medicine
Schools of Medicine
United States
Zip Code
Zhang, Yuqing; Coogan, Patricia F; Palmer, Julie R et al. (2010) A case-control study of reproductive factors, female hormone use, and risk of pancreatic cancer. Cancer Causes Control 21:473-8
Coogan, Patricia F; Kelly, Judith Parsells; Strom, Brian L et al. (2010) Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf 19:752-5
Zhang, Yuqing; Coogan, Patricia; Palmer, Julie R et al. (2009) Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control 20:691-8
Coogan, Patricia F; Strom, Brian L; Rosenberg, Lynn (2009) Antidepressant use and colorectal cancer risk. Pharmacoepidemiol Drug Saf 18:1111-4
Rosenberg, Lynn; Zhang, Yuqing; Coogan, Patricia F et al. (2009) A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 169:473-9
Kelly, Judith P; Coogan, Patricia; Strom, Brian L et al. (2008) Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 17:322-7
Coogan, Patricia F; Strom, Brian L; Rosenberg, Lynn (2008) SSRI use and breast cancer risk by hormone receptor status. Breast Cancer Res Treat 109:527-31
Coogan, Patricia F; Rosenberg, Lynn; Strom, Brian L (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213-9
Zhang, Yuqing; Coogan, Patricia F; Palmer, Julie R et al. (2006) Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev 30:99-101
Zhang, Yuqing; Coogan, Patricia F; Palmer, Julie R et al. (2005) Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 162:165-70

Showing the most recent 10 out of 35 publications